BiotechTube

Livmarli + Livmarli

Pre-clinicalRecruiting
0 watching 0 views this week💤 Quiet
20
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Alagille Syndrome

Conditions

Alagille Syndrome, Progressive Familial Intrahepatic Cholestasis

Trial Timeline

Sep 21, 2023 → Sep 20, 2030

NCT ID
NCT06193928

About Livmarli + Livmarli

Livmarli + Livmarli is a pre-clinical stage product being developed by Mirum Pharmaceuticals for Alagille Syndrome. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06193928. Target conditions include Alagille Syndrome, Progressive Familial Intrahepatic Cholestasis.

Hype Score Breakdown

Clinical
5
Activity
2
Company
7
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT06193928Pre-clinicalRecruiting

Competing Products

9 competing products in Alagille Syndrome

See all competitors
ProductCompanyStageHype Score
Odevixibat + PlaceboIpsenPhase 3
74
OdevixibatIpsenPhase 3
74
LUM001 (Maralixibat)Mirum PharmaceuticalsPhase 2
49
maralixibatMirum PharmaceuticalsPre-clinical
20
LUM001 (Maralixibat)Mirum PharmaceuticalsPhase 2
49
LUM001 (Maralixibat) + PlaceboMirum PharmaceuticalsPhase 2
49
Livmarli Oral ProductMirum PharmaceuticalsApproved
82
LUM001 + PlaceboMirum PharmaceuticalsPhase 2
49
LUM001 + PlaceboMirum PharmaceuticalsPhase 2
49

Other Products from Mirum Pharmaceuticals

Livmarli Oral ProductApproved
82
MaralixibatPhase 3
74
Cholic AcidsPhase 3
74
MaralixibatPhase 3
74
Cholic acidPhase 3
74